Antibody-based therapies to address evolving viral threats
Invivyd is a clinical-stage biopharmaceutical company developing antibody-based medicines to protect against serious viral respiratory diseases. Using its proprietary INVYMAB platform, which combines viral surveillance, predictive modeling, and advanced antibody engineering, the company aims to create medicines more potent and resistant to viral evolution than the human immune system. Key programs target COVID-19, RSV, and measles.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2021
Apr 2021
Jan 2021
Oct 2020
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
